By finding the important interaction sites between Bcr-Abl and HSP90AB1, our study provides the basis for clinical development of HSP90 inhibitors in treating CML and other Bcr-Abl-addicted malignancies. Here, HSP90AA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.